GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Khiron Life Sciences Corp (OTCPK:KHRWF) » Definitions » Net Change in Cash

Khiron Life Sciences (Khiron Life Sciences) Net Change in Cash : $-10.31 Mil (TTM As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Khiron Life Sciences Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Khiron Life Sciences's Net Change in Cash for the three months ended in Sep. 2022 was $-2.91 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2022 was $-10.31 Mil.

Khiron Life Sciences Net Change in Cash Historical Data

The historical data trend for Khiron Life Sciences's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Khiron Life Sciences Net Change in Cash Chart

Khiron Life Sciences Annual Data
Trend May12 May13 May14 May15 May16 May17 Dec18 Dec19 Dec20 Dec21
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 9.83 -4.30 9.61 -9.94

Khiron Life Sciences Quarterly Data
Nov17 Feb18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.65 -4.94 -3.00 0.54 -2.91

Khiron Life Sciences Net Change in Cash Calculation

Khiron Life Sciences's Net Change in Cash for the fiscal year that ended in Dec. 2021 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-15.938+-1.63+8.512+-0.888
=-9.94

Khiron Life Sciences's Net Change in Cash for the quarter that ended in Sep. 2022

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-3.781+-0.654+0.648+0.879
=-2.91

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Khiron Life Sciences Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Khiron Life Sciences's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Khiron Life Sciences (Khiron Life Sciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Khiron Life Sciences Corp (OTCPK:KHRWF) » Definitions » Net Change in Cash
Comparable Companies
TSX:WLLW TSX:DN XCNQ:RAMM TSX:ASP XCNQ:ICAN TSXV:NDVA TSX:AH XCNQ:LOWL XCNQ:NVG TSX:NEPT XTER:MRK ZTS TSE:4502 NSE:SUNPHARMA CTLT TSE:4507 SHSE:600196 SZSE:000538 VTRS NSE:DIVISLAB
Traded in Other Exchanges
N/A
Address
2300 - 500 Burrard Street, Vancouver, BC, CAN, V6C 2B5
Website
https://www.khiron.ca
Khiron Life Sciences Corp is a vertically integrated medical company with core operations in Latin America and Europe, The company's platform leverages medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific, product innovation, and cannabis operations expertise to drive prescriptions and brand loyalty with patients worldwide. The company has a presence in Mexico, Peru, Germany, the United Kingdom, and Brazil.